08:00 - 09:15
Adam Cunningham, BactiVac Network Co-Director, University of Birmimgham, UK
09:15 - 09:25
Professor Ian MacLennan, Emeritus Professor of Immunology, University of Birmingham, UK
09:25 - 10:00
Catrin Moore, Senior Lecturer, St George's University of London, UK
10:00 - 10:30
Mateusz Hasso-Agopsowicz, Technical Officer, WHO, Switzerland
10:30 - 11:00
11:00 - 11:30
Mark Stevens, Chair of Microbial Pathogenesis & Deputy Director, The Roslin Institute, University of Edinburgh, UK
11:30 - 12:00
Hester Nichols, Project Lead, The Vaccine Group Ltd, UK
12:00 - 12:13
Verena Lentsch, PhD student, ETH Zurich, Switzerland
12:13 - 12:26
Rory Hills, Graduate student, University of Oxford, UK
12:26 - 12:39
12:40 - 13:40
Angela Brueggemann, Professor of Infectious Disease Epidemiology, University of Oxford, UK
13:40 - 14:10
Cristina Alaimo, Clinical Director, LimmaTech Biologics, Switzerland
14:10 - 14:23
Sophie Higham, Research Assistant, Imperial College London, UK
14:23 - 14:36
Giuseppe Ercoli, Research Associate, UCL, UK
14:36 - 14:39
Jose Bengoechea, Director, Wellcome Wolfson Institute for Experimental Medicine, Queen's University Belfast, UK
14:50 - 15:20
Suzan HM Rooijakkers, Professor, University Medical Centre Utrecht, The Netherlands
15:20 - 15:50
15:50 - 16:00
16:00 - 16:15
16:15 - 17:30
17:30 - 19:00
19:00 - 21:00
Camille Locht, Research Director, Inserm / Institut Pasteur de Lille, France
09:00 - 09:30
Caroline Zellmer, PhD student, University of Cambridge, UK
09:30 - 09:43
Omar Rossi, Lab Head serology and immunology, GSK Vaccines Institute for Global Health, Italy
09:43 - 09:56
Francesca Micoli, Senior Project Leader and Director of GVGH Innovation Academy, GSK Vaccines Institute for Global Health, Italy
09:56 - 10:09
Ian Henderson, Executive Director, Institute for Molecular Bioscience, The University of Queensland, Australia
10:10 - 10:40
10:40 - 11:10
Brendan Wren, London School of Hygiene and Tropical Medicine, UK
11:10 - 11:40
Galit Alter, VP Immunology, Moderna, USA
11:40 - 12:10
12:10 - 13:10
Cal MacLennan, BactiVac Network Director, University of Birmingham, UK
13:10 - 13:40
Dr Christine Rollier, Professor of Vaccinology, University of Surrey, UK
14:10 - 14:40
Adam Dale, NIHR Academic Clinical Lecturer in Infectious Diseases & Medical Microbiology, University of Southampton, UK
14:40 - 15:10
Naina McCann, Clinical Research Fellow / DPhil Student, Oxford Vaccine Group, UK
15:10 - 15:40
Constantino López-Macías, Medical Research Unit on Immunochemistry, National Medical Centre “Siglo XXI”/Mexican Institute for Social Security, Mexico
15:40 - 16:10
Adam Cunningham, BactiVac Network Co-Director, University of Birmingham, UK
16:10 - 16:30
Registration
Adam Cunningham, BactiVac Network Co-Director, University of Birmimgham, UK Welcome
Professor Ian MacLennan, Emeritus Professor of Immunology, University of Birmingham, UK Keynote Lecture - Affinity maturation and persistence of antibody responses
Catrin Moore, Senior Lecturer, St George's University of London, UK Session 1: AMR - the problem in the context of human and veterinary health
Mateusz Hasso-Agopsowicz, Technical Officer, WHO, Switzerland Session 1: AMR - the problem in the context of human and veterinary health
Session 1: AMR - the problem in the context of human and veterinary health
Mark Stevens, Chair of Microbial Pathogenesis & Deputy Director, The Roslin Institute, University of Edinburgh, UK Session 1: AMR - the problem in the context of human and veterinary health
Hester Nichols, Project Lead, The Vaccine Group Ltd, UK Session 1: AMR - the problem in the context of human and veterinary health
Verena Lentsch, PhD student, ETH Zurich, Switzerland Session 1: AMR - the problem in the context of human and veterinary health
Rory Hills, Graduate student, University of Oxford, UK Session 1: AMR - the problem in the context of human and veterinary health
Angela Brueggemann, Professor of Infectious Disease Epidemiology, University of Oxford, UK Session 2: The strengths and gaps in using vaccination to limit AMR
Cristina Alaimo, Clinical Director, LimmaTech Biologics, Switzerland Session 2: The strengths and gaps in using vaccination to limit AMR
Sophie Higham, Research Assistant, Imperial College London, UK Session 2: The strengths and gaps in using vaccination to limit AMR
Giuseppe Ercoli, Research Associate, UCL, UK Session 2: The strengths and gaps in using vaccination to limit AMR
Jose Bengoechea, Director, Wellcome Wolfson Institute for Experimental Medicine, Queen's University Belfast, UK Session 3: Host responses to different bacterial antigens and vaccines - key lessons learned
Suzan HM Rooijakkers, Professor, University Medical Centre Utrecht, The Netherlands Session 3: Host responses to different bacterial antigens and vaccines - key lessons learned
Session 3: Host responses to different bacterial antigens and vaccines - key lessons learned
Drinks reception
Conference Dinner
Camille Locht, Research Director, Inserm / Institut Pasteur de Lille, France Session 3 continued: Host responses to different bacterial antigens and vaccines - key lessons learned
Caroline Zellmer, PhD student, University of Cambridge, UK Session 3 continued: Host responses to different bacterial antigens and vaccines - key lessons learned
Omar Rossi, Lab Head serology and immunology, GSK Vaccines Institute for Global Health, Italy Session 3 continued: Host responses to different bacterial antigens and vaccines - key lessons learned
Francesca Micoli, Senior Project Leader and Director of GVGH Innovation Academy, GSK Vaccines Institute for Global Health, Italy Session 3 continued: Host responses to different bacterial antigens and vaccines - key lessons learned
Ian Henderson, Executive Director, Institute for Molecular Bioscience, The University of Queensland, Australia Session 4: Enhancing the use of existing and novel platforms, technologies, adjuvants - the spectre of 'Pathogen X'
Session 4: Enhancing the use of existing and novel platforms, technologies, adjuvants - the spectre of 'Pathogen X'
Brendan Wren, London School of Hygiene and Tropical Medicine, UK Session 4: Enhancing the use of existing and novel platforms, technologies, adjuvants - the spectre of 'Pathogen X'
Galit Alter, VP Immunology, Moderna, USA Session 4: Enhancing the use of existing and novel platforms, technologies, adjuvants - the spectre of 'Pathogen X'
Cal MacLennan, BactiVac Network Director, University of Birmingham, UK Session 5: The targeting of bacterial pathogens to reduce AMR - addressing unmet needs
Dr Christine Rollier, Professor of Vaccinology, University of Surrey, UK Session 5: The targeting of bacterial pathogens to reduce AMR - addressing unmet needs
Session 5: The targeting of bacterial pathogens to reduce AMR - addressing unmet needs
Adam Dale, NIHR Academic Clinical Lecturer in Infectious Diseases & Medical Microbiology, University of Southampton, UK Session 5: The targeting of bacterial pathogens to reduce AMR - addressing unmet needs
Naina McCann, Clinical Research Fellow / DPhil Student, Oxford Vaccine Group, UK Session 5: The targeting of bacterial pathogens to reduce AMR - addressing unmet needs
Constantino López-Macías, Medical Research Unit on Immunochemistry, National Medical Centre “Siglo XXI”/Mexican Institute for Social Security, Mexico Session 5: The targeting of bacterial pathogens to reduce AMR - addressing unmet needs
Adam Cunningham, BactiVac Network Co-Director, University of Birmingham, UK Session 5: The targeting of bacterial pathogens to reduce AMR - addressing unmet needs